The emergence and spread of antimicrobial resistance have been identified as a significant problem for human health that profoundly impacts clinical outcomes and healthcare-associated costs. The overuse and misuse of antibiotics have resulted in antimicrobial resistance, as antibiotics are commonly prescribed without a definitive diagnosis. Antibiotic stewardship is the effort by healthcare providers to measure and improve how antibiotics are prescribed by clinicians and used by patients. It includes prescribing antibiotics only when needed (i.e., for bacterial infections, not viral ones), prescribing the appropriate antibiotics for the diagnosed infection, prescribing the correct dose and duration of antibiotic treatment, and combat antibiotic resistance. Hence, biomarkers have emerged as potentially useful diagnostic tools to help physicians triage, diagnose, stratify risk, and monitor the clinical course and respond to antibiotics. PCT (procalcitonin) is the most widely studied biomarker for antibiotic stewardship. It has been tested to aid the initiation or discontinuation of antibiotics, both in children and adults.
MARKET SCOPE
The "Global Antibiotic Stewardship Biomarkers Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the antibiotic stewardship biomarkers market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading antibiotic stewardship biomarkers market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
-Based on type, the global antibiotic stewardship biomarkers market is segmented into blood biomarkers and urine biomarkers.
-On the basis of application, the market is bifurcated into diagnostics, drug discovery, personalized medicine and others.
MARKET DYNAMICS
Drivers
-Rising diagnostic applications of biomarkers drive the antibiotic stewardship biomarkers market.
-Increasing research and development activities propel the market growth.
-Technological advancement in disease diagnosis and increasing lower respiratory tract infections fuel the market growth.
-Antibiotic stewardship biomarkers act as cornerstones in the treatment of infection that boosts the market growth.
Restraints
-Insufficient microbiological information.
-Limited drug availability.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The antibiotic stewardship biomarkers market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the antibiotic stewardship biomarkers market in these regions.
IMPACT OF COVID-19 ON ANTIBIOTIC STEWARDSHIP BIOMARKERS MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. During COVID-19, the antibiotic stewardship biomarkers market witnessed growth as biomarkers were used to predict secondary infections in ICU patients. CRP was usually increased in patients with COVID-19, and serum procalcitonin (PCT) helps in the identification of secondary infections in patients with COVID-19. It was found that a high proportion of COVID-19 patients received unnecessary antibiotic treatment. The increase in antibiotic administration can result in antibiotic resistance. Hence, it was suggested that a potential consequence of the COVID-19 pandemic might be an accelerated propagation of antimicrobial resistance. Therefore, clinicians, hospitals, microbiology labs, and public health organizations need to monitor the potential impact of increased antimicrobial consumption on the emergence of resistance in patients. The overall results from carefully designed studies can be utilized to prescribe rational antimicrobial treatment and stewardship strategies and develop diagnostic criteria for secondary bacterial infections in the future.
MARKET PLAYERS
The report covers key developments in the antibiotic stewardship biomarkers market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from antibiotic stewardship biomarkers market are anticipated to have lucrative growth opportunities in the future with the rising demand for antibiotic stewardship biomarkers in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the antibiotic stewardship biomarkers market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
-Thermo Fisher Scientific
-Qiagen
-Merck
-Abbott
-Bio-Rad Laboratories
-Roche
-HiMedia Laboratories
-Danaher Corporation
-Creative Diagnostic
-Agilent Technologies
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.